Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-authorisation/Post-marketing Observational Study to Evaluate the Association Between Exposure to AZD1222 and Safety Concerns Using Existing Secondary Health Data Sources

NCT05126992 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05126992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05126992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-authorisation/Post-marketing Observational Study to Evaluate the Association Between Exposure to AZD1222 and Safety Concerns Using Existing Secondary Health Data Sources
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
February 18, 2022
Completion date
January 24, 2024
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, vaccine adverse events of special interest